GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » EV-to-EBIT

MaxCyte (LSE:MXCT) EV-to-EBIT : -4.73 (As of May. 08, 2024)


View and export this data going back to 2016. Start your Free Trial

What is MaxCyte EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MaxCyte's Enterprise Value is £184.03 Mil. MaxCyte's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-38.88 Mil. Therefore, MaxCyte's EV-to-EBIT for today is -4.73.

The historical rank and industry rank for MaxCyte's EV-to-EBIT or its related term are showing as below:

LSE:MXCT' s EV-to-EBIT Range Over the Past 10 Years
Min: -121.13   Med: -20   Max: -2.01
Current: -4.74

During the past 12 years, the highest EV-to-EBIT of MaxCyte was -2.01. The lowest was -121.13. And the median was -20.00.

LSE:MXCT's EV-to-EBIT is ranked worse than
100% of 457 companies
in the Medical Devices & Instruments industry
Industry Median: 20.72 vs LSE:MXCT: -4.74

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. MaxCyte's Enterprise Value for the quarter that ended in Dec. 2023 was £248.33 Mil. MaxCyte's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-38.88 Mil. MaxCyte's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -15.66%.


MaxCyte EV-to-EBIT Historical Data

The historical data trend for MaxCyte's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte EV-to-EBIT Chart

MaxCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.92 -34.50 -42.50 -12.22 -6.51

MaxCyte Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.22 -7.58 -6.04 -3.24 -6.51

Competitive Comparison of MaxCyte's EV-to-EBIT

For the Medical Devices subindustry, MaxCyte's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MaxCyte's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MaxCyte's EV-to-EBIT falls into.



MaxCyte EV-to-EBIT Calculation

MaxCyte's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=184.032/-38.882
=-4.73

MaxCyte's current Enterprise Value is £184.03 Mil.
MaxCyte's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was £-38.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MaxCyte  (LSE:MXCT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

MaxCyte's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-38.882/248.32505
=-15.66 %

MaxCyte's Enterprise Value for the quarter that ended in Dec. 2023 was £248.33 Mil.
MaxCyte's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was £-38.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MaxCyte EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of MaxCyte's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


MaxCyte (LSE:MXCT) Business Description

Traded in Other Exchanges
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.